J&J reports Phase 1 data for prostate cancer combination pasritamig and JNJ-9401

Johnson & Johnson reported Phase 1 results for its investigational combination of pasritamig and JNJ-9401, two bispecific antibodies, showing a 73% PSA response rate in 15 heavily pretreated advanced prostate cancer patients, with 47% achieving deep PSA declines of 90% or more. The combination is being evaluated in the Phase 3 KLK2-comPAS trial.

Detected & updated continuously · Source: Nebula